Respiratory Infections News

The FDA’s authorization on Thursday of booster shots for adolescents aged 16 and 17 years came just 2 days before the 1-year anniversary of the first emergency use authorization of a COVID-19 vaccine in the United States.

According to a new report, global funding for tuberculosis research totaled $915 million in 2020 — less than half of the $2 billion goal set at the 2018 United Nations High-Level Meeting on TB.

The FDA on Thursday authorized booster doses of the Pfizer-BioNTech COVID-19 vaccine for children aged 16 and 17 years.

Patients with COVID-19 reported sleep, neurological and other symptoms that often lasted for more than a year, according a retrospective, observational analysis at one health care system.

Pfizer and BioNTech said Wednesday that two doses of their COVID-19 vaccine “may not” offer sufficient protection against the omicron variant of SARS-CoV-2, but a third dose appears to improve protection.

National Institute of Allergy and Infectious Diseases Director Anthony S. Fauci, MD, said Tuesday that the omicron variant of SARS-CoV-2 might cause less severe COVID-19 illness.

Researchers found no pattern of multisystem inflammatory syndrome in adults following COVID-19 vaccination without previous SARS-CoV-2 infection, according to a study published in Clinical Infectious Diseases.

Usual interstitial pneumonia was a common finding in lung biopsies of people evaluated for post-COVID-19 interstitial lung disease, according to data published in EClinicalMedicine.

Six COVID-19 vaccines increased protection when given as booster shots 10 to 12 weeks after a two-dose primary series of the Pfizer-BioNTech vaccine, according to results from a randomized controlled trial published in The Lancet.

Among countries hosting COVID-19 vaccine trials, higher income countries have received proportionally more doses of authorized COVID-19 vaccines, making it easier for them to vaccinate their population, a study found.